Analysts Offer Insights on Healthcare Companies: OncoSec Medical (NASDAQ: ONCS) and Heron Therapeutics (NASDAQ: HRTX)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OncoSec Medical (NASDAQ: ONCS) and Heron Therapeutics (NASDAQ: HRTX) with bullish sentiments.

OncoSec Medical (NASDAQ: ONCS)

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares closed yesterday at $1.65, close to its 52-week low of $1.36.

McCarthy said:

“Oncosec announced data demonstrating that the combination of DNA-based IL-12 and Keytruda (anti-PD-1) induced a 40% overall response rate (ORR, 6/15) in a population of melanoma patients that were classified as non-responders to checkpoint therapy.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -20.8% and a 19.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Stellar Biotechnologies, and Inovio Pharmaceuticals.

OncoSec Medical has an analyst consensus of Moderate Buy.

Heron Therapeutics (NASDAQ: HRTX)

In a report released yesterday, Boris Peaker from Cowen & Co. reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX). The company’s shares closed yesterday at $17.85.

Peaker wrote:

“Last night Heron reported 3Q16 financial and operational results.”

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.8% and a 37.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Corvus Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Heron Therapeutics is Strong Buy and the average price target is $41, representing a 129.7% upside.

In a report issued on October 26, Aegis Capital also initiated coverage with a Buy rating on the stock with a $41 price target.